BioAffinity Soars On Strong Preliminary Sales Growth Of CyPath Lung Test
(RTTNews) - Shares of bioAffinity Technologies Inc. (BIAF) are up over 10% in Wednesday's trading, after the company announced stronger-than-expected unit growth in the first quarter of 2026 for its noninvasive diagnostic test, CyPath Lung.
CyPath Lung is a noninvasive test to improve the early detection of lung cancer in patients at high risk for the disease. It can be used alone or in combination with other diagnostic tools. This test supports lung cancer risk assessment, pulmonary nodule management and post-treatment surveillance.
According to the company, based on preliminary unaudited data, the unit sales of CyPath Lung increased 146% year-over-year in the first quarter of 2026, significantly exceeding internal expectations.
bioAffinity Technologies attributed the strong performance to accelerating physician adoption and expanding clinical utilization of the diagnostic test, which combines flow cytometry and AI to improve lung cancer risk assessment and nodule management.
BIAF has traded in a range of $0.69 to $32.10 in the last 1 year. A 1-for-30 reverse stock split was implemented on September 19, 2025. The stock is currently trading at $4.21, up 10%.
